NCT03941743 is a Phase 1 clinical trial of Fingolimod in Breast Carcinoma, sponsored by Mayo Clinic.

Who is sponsoring NCT03941743?

NCT03941743 is sponsored by Mayo Clinic.

What drugs are being tested in NCT03941743?

Interventions in NCT03941743: Fingolimod, Fingolimod Hydrochloride, Questionnaire Administration.

What condition does NCT03941743 study?

NCT03941743 studies Breast Carcinoma.

Is NCT03941743 still recruiting?

NCT03941743 is currently completed. Last updated 21 July 2023.

Last reviewed 2023-07-21 · How we verify

NCT03941743

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer

Completed Phase 1 Last updated 21 July 2023

What this trial tests

Phase 1 trial testing Fingolimod in Breast Carcinoma in 2 participants. Completed in 23 November 2021.

Timeline

12 December 2019

Primary endpoint
5 June 2020

23 November 2021

Quick facts

Lead sponsor	Mayo Clinic
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	2
Start date	12 December 2019
Primary completion	5 June 2020
Estimated completion	23 November 2021
Sites	3 locations across United States

Drugs / interventions tested

Fingolimod (FINGOLIMOD) — full drug profile →
Fingolimod Hydrochloride — full drug profile →
Questionnaire Administration

Conditions studied

Breast Carcinoma — all drugs for Breast Carcinoma →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial phase I studies how well fingolimod works in preventing chemotherapy-induced nerve pain (neuropathy) in patients with breast cancer who are taking paclitaxel. Fingolimod acts by suppressing immune reactions in the brain. This study is being done to see if fingolimod can reduce neuropathy caused by paclitaxel.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy.
Yamamoto S, Egashira N. · · 2021 · cited 86× · PMID 33477371 · DOI 10.3390/ijms22020888
Chemotherapy-induced peripheral neuropathy-part 2: focus on the prevention of oxaliplatin-induced neurotoxicity.
Sałat K. · · 2020 · cited 73× · PMID 32347537 · DOI 10.1007/s43440-020-00106-1
The S1P-S1PR Axis in Neurological Disorders-Insights into Current and Future Therapeutic Perspectives.
Lucaciu A, Brunkhorst R, Pfeilschifter JM, Pfeilschifter W, et al · · 2020 · cited 53× · PMID 32580348 · DOI 10.3390/cells9061515
Targeting Sphingolipid Metabolism as a Therapeutic Strategy in Cancer Treatment.
Janneh AH, Ogretmen B. · · 2022 · cited 48× · PMID 35565311 · DOI 10.3390/cancers14092183
The Role of Sphingolipids Metabolism in Cancer Drug Resistance.
Bataller M, Sánchez-García A, Garcia-Mayea Y, Mir C, et al · · 2021 · cited 47× · PMID 35004331 · DOI 10.3389/fonc.2021.807636
Targeting the Sphingosine-1-Phosphate Axis for Developing Non-narcotic Pain Therapeutics.
Squillace S, Spiegel S, Salvemini D. · · 2020 · cited 38× · PMID 33010954 · DOI 10.1016/j.tips.2020.09.006
Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.
Chua KC, Xiong C, Ho C, Mushiroda T, et al · · 2020 · cited 30× · PMID 32562552 · DOI 10.1002/cpt.1958
Signaling controversy and future therapeutical perspectives of targeting sphingolipid network in cancer immune editing and resistance to tumor necrosis factor-α immunotherapy.
Sukocheva OA, Neganova ME, Aleksandrova Y, Burcher JT, et al · · 2024 · cited 26× · PMID 38698424 · DOI 10.1186/s12964-024-01626-6

Verify or expand the search:

Other trials of Fingolimod

Trials testing the same drug.

NCT07483632 — A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses · Phase 3 · not yet recruiting
NCT07220252 — Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis · Phase 2, PHASE3 · not yet recruiting
NCT06408259 — Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relap · Phase 3 · recruiting
NCT06087965 — Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage · Phase 1, PHASE2 · unknown
NCT05123703 — A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Re · Phase 3 · active not recruiting

Other recruiting trials for Breast Carcinoma

Currently open trials in the same condition.

NCT07067138 — A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS- · NA · recruiting
NCT07291414 — A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients · NA · recruiting
NCT07338721 — Does Ultrasound Guidance Axillary Incision Improve Sentinel Lymph Node Detection in Breast Cancer? · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors · Phase 2 · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03941743 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 21 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03941743.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing